Asset Details
Do you wish to reserve the book?
Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes
Do you wish to request the book?
Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes
2016
Overview
Acute liver failure （ALF） is a life-threatening illness. The extracorporeal cell-based bioartiflcial liver （BAL） system could bridge liver transplantation and facilitate liver regeneration for ALF patients by providing met- abolic detoxification and synthetic functions. Previous BAL systems, based on hepatoma cells and non-human hepatocytes, achieved limited clinical advances, largely due to poor hepatic functions, cumbersome preparation or safety concerns of these cells. We previously generated human functional hepatocytes by lineage conversion （hiHeps）. Here, by improving functional maturity of hiHeps and producing hiHeps at clinical scales （3 billion cells）, we developed a hiHep-based BAL system （hiHep-BAL）. In a porcine ALF model, hiHep-BAL treatment restored liver functions, corrected blood levels of ammonia and bilirubin, and prolonged survival. Importantly, human albumin and a-l-antitrypsin were detectable in hiHep-BAL-treated ALF pigs. Moreover, hiHep-BAL treatment led to attenuated liver damage, resolved inflammation and enhanced liver regeneration. Our findings indicate a promising clinical application of the hiHep-BAL system.
Publisher
Nature Publishing Group UK,Nature Publishing Group
